AZD1446 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild to Moderate Alzheimer's Disease
Conditions
Mild to Moderate Alzheimer's Disease
Trial Timeline
Dec 1, 2009 → Jul 1, 2010
NCT ID
NCT01039701About AZD1446 + Placebo
AZD1446 + Placebo is a phase 2 stage product being developed by AstraZeneca for Mild to Moderate Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01039701. Target conditions include Mild to Moderate Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01199315 | Phase 1 | Completed |
| NCT01039701 | Phase 2 | Completed |
| NCT01021189 | Phase 1 | Completed |
| NCT00997308 | Phase 1 | Completed |
| NCT00902993 | Phase 1 | Completed |
Competing Products
20 competing products in Mild to Moderate Alzheimer's Disease